The advice patients received about hormone therapy in 2005 is not the advice supported in 2026. The labeling on the products themselves has changed. If you were told a decade ago that hormone therapy was off the table, that conversation is worth reopening with a clinician who has read the current guidance.
This guide covers what changed, who is a reasonable candidate, how the delivery routes differ, what testosterone therapy involves for men, and what the first year of monitoring actually looks like.
What Changed, and When
In November 2025, the FDA requested labeling changes across menopausal hormone therapy products, asking manufacturers to remove boxed warnings covering cardiovascular disease, breast cancer, and probable dementia, and to remove the “lowest dose for the shortest duration” boxed language. An endometrial cancer boxed warning was retained only for systemic estrogen-alone products. The revised labeling directs prescribers to consider therapy for moderate-to-severe vasomotor symptoms in women under 60 or within 10 years of menopause, and to present the Women’s Health Initiative data specific to ages 50 to 59.
In February 2026, the FDA approved the first set of revised labels. The rollout is ongoing, so labeling still varies by product and manufacturer at the time of writing.
Two clarifications matter more than the headline.
Removing a boxed warning does not delete a risk. Venous thromboembolism, ischemic stroke, and gallbladder disease remain in the Warnings and Precautions sections. Clinicians and patient advocacy groups have cautioned against a pendulum swing in the opposite direction, particularly for breast cancer survivors.
And the labeling change did not come from new trial data. It came from re-reading existing data by age group.
How the WHI Findings Were Reinterpreted
The Women’s Health Initiative arms halted in 2002 and 2004 produced two decades of avoidance. The reinterpretation is stratified by age and by regimen:
- Women aged 50 to 59 treating vasomotor symptoms showed a favorable benefit-risk profile.
- Women aged 60 to 69 required more caution and individualized assessment.
- Women aged 70 and older showed substantially elevated cardiovascular risk, and initiation at that age is generally avoided.
- The breast cancer signal appeared in the estrogen-plus-progestogen arm. The estrogen-alone arm showed little or no increase.
The Menopause Society’s position statement, still the 2022 document at the time of writing, frames this as the timing hypothesis: benefit-risk is most favorable when therapy starts under age 60 or within 10 years of the final menstrual period.
Are You a Candidate?
Candidacy is not a yes or no answer. It is a combination of symptom burden, timing, uterine status, and contraindications.
| Factor | Favorable | Requires Careful Discussion | Generally Not Appropriate |
|---|---|---|---|
| Age | Under 60 | 60 to 69 | 70 and older for new initiation |
| Time since menopause | Within 10 years | 10 to 15 years | More than 15 years for new systemic therapy |
| Symptom severity | Moderate to severe hot flashes, night sweats, sleep disruption | Mild symptoms | Symptoms absent |
| Uterus present | Estrogen plus progestogen required | Same | Estrogen alone is not appropriate with an intact uterus |
| VTE or stroke history | None | Family history, obesity, immobility | Active or prior clot, prior stroke |
| Breast cancer history | None | Family history without a personal diagnosis | Estrogen-sensitive cancer history |
| Liver disease | Normal function | Mild abnormalities | Active liver disease |
| Unexplained vaginal bleeding | None | Investigated and resolved | Present and uninvestigated |
Genitourinary symptoms sit in their own category. Vaginal dryness, painful intercourse, and recurrent urinary symptoms respond to low-dose local vaginal estrogen, which produces minimal systemic absorption. Its safety profile differs meaningfully from systemic therapy, and it remains an option for many women who are not candidates for systemic treatment. That decision still belongs with your clinician, particularly after breast cancer.
Delivery Routes Are Not Interchangeable
Route changes risk, not just convenience. Oral estrogen passes through the liver first, which raises clotting factors, triglycerides, and gallstone risk. Transdermal delivery bypasses that first pass.
| Route | How It Works | Clinical Notes | Practical Considerations |
|---|---|---|---|
| Oral tablet | Daily pill | First-pass liver metabolism; associated with higher VTE risk than transdermal | Simple, widely covered by insurance |
| Transdermal patch | Applied 1–2 times weekly | Avoids first pass; often preferred with migraine, obesity, smoking history, or clot risk factors | Adhesion issues in heat and humidity |
| Gel or spray | Applied daily to skin | Same first-pass advantage; flexible dosing | Transfer risk to others until dry |
| Vaginal cream, tablet, or ring | Local application | Minimal systemic absorption; targets genitourinary symptoms | Does not treat hot flashes at low local doses |
| Compounded pellets | Implanted every few months | No FDA-approved compounded estradiol pellet; professional societies have raised concerns about dose consistency, supraphysiologic levels, and non-removability | Usually cash-pay; cannot be stopped quickly if problems arise |
The word “bioidentical” is used two different ways, and the distinction is financial as well as clinical. FDA-approved bioidentical options exist, including estradiol and micronized progesterone, and they are regulated, dose-verified, and typically covered by insurance. Custom-compounded formulations are not FDA-approved as products, and major professional societies do not recommend them when approved alternatives exist. Salivary hormone testing, frequently sold alongside compounded regimens, is not supported for dosing decisions.
If you have a uterus, a progestogen is mandatory alongside systemic estrogen. Unopposed estrogen drives endometrial hyperplasia and cancer risk. Micronized progesterone at 100 to 200 mg nightly is a common approach.
Our hormone replacement therapy program starts with a full history and baseline labs rather than a product recommendation.
Testosterone Therapy for Men
Men face a different evidence base and a different set of marketing pressures.
Diagnosis requires more than symptoms. Fatigue, low libido, and reduced muscle mass overlap with sleep apnea, depression, thyroid disease, obesity, and poor sleep. The diagnostic standard is a fasting morning total testosterone below roughly 300 ng/dL, confirmed on a second morning draw. A single afternoon test is not sufficient, and clinics that treat one number are skipping the step that matters.
The TRAVERSE trial, published in 2023, enrolled 5,246 men with hypogonadism and elevated cardiovascular risk. Major adverse cardiac events occurred in 7.0% of the testosterone group versus 7.3% on placebo, meeting non-inferiority. The trial also found excess atrial fibrillation, 3.5% versus 2.4%, plus higher rates of acute kidney injury and pulmonary embolism.
In February 2025, the FDA implemented class-wide labeling changes for testosterone products: the boxed cardiovascular warning language was removed and replaced with TRAVERSE data, the limitation of use for age-related hypogonadism was retained, and a class-wide blood pressure warning was added after ambulatory monitoring studies confirmed increases.
Monitoring is not optional:
- Testosterone level and hematocrit at 3 to 6 months, then annually
- Therapy is typically held or adjusted if hematocrit exceeds roughly 54%; a baseline above roughly 48% is a contraindication to starting
- PSA at baseline and annually for men 40 and older
- Blood pressure at every visit
- Fertility counseling before starting, because testosterone therapy suppresses sperm production and is inappropriate for men planning conception in the near term
Baseline evaluation frequently uncovers a different cause. On-site lab testing and a review of thyroid and metabolic function through endocrine care often explain the symptoms without hormone therapy at all.
Your First Year: A Monitoring Calendar
| Timepoint | Women (Menopausal Hormone Therapy) | Men (Testosterone Therapy) |
|---|---|---|
| Baseline | History, blood pressure, BMI, lipids, TSH, mammogram current, pelvic exam and bleeding history, VTE and cancer risk review | Two fasting morning testosterone levels, CBC with hematocrit, PSA if 40+, blood pressure, sleep apnea screening, fertility discussion |
| Month 3 | Symptom response, side effects, bleeding pattern, blood pressure, dose adjustment | Testosterone level, hematocrit, blood pressure, symptom response |
| Month 6 | Reassess symptoms and route; investigate any persistent bleeding | Testosterone level, hematocrit, PSA if indicated |
| Month 12 | Annual exam, breast assessment and imaging per schedule, blood pressure, lipids, decision on continuation | Testosterone, hematocrit, PSA, blood pressure, lipids |
| Ongoing | Annual reassessment of benefit-risk; no routine hormone level monitoring is required for standard menopausal therapy | Annual labs indefinitely while on therapy |
Call your clinician between visits for: new or worsening headaches, chest pain, shortness of breath, calf pain or swelling, vaginal bleeding that persists past 3 to 6 months of therapy, breast lumps, or new severe mood changes.
Routine blood hormone level checks are not required for standard menopausal therapy, because symptom relief is the endpoint. Clinics that bill frequent hormone panels to justify dose changes are running a business model, not a monitoring protocol.
Cost, Coverage, and the Clinics Selling You Something
This is the section almost no health publisher writes, and it determines what patients actually do.
FDA-approved oral estradiol, transdermal patches, and micronized progesterone are widely available as generics and are typically covered by commercial insurance and Medicare Part D, subject to formulary and deductible. Testosterone gels and injections are similarly covered when documented hypogonadism is established.
Compounded pellet programs are usually cash-pay, often sold as multi-visit packages with insertion fees several times a year, and they cannot be reversed once implanted. Telehealth hormone startups typically bundle a subscription and a shipped product, which works for straightforward cases but leaves the baseline workup, physical exam, and complication management to someone else.
Three questions cut through most of it:
- Is the product you are prescribing FDA-approved, or compounded?
- What labs will be drawn, at what intervals, and who reviews them?
- What is the total 12-month cost, including visits, labs, and refills?
Verify coverage on our insurance and payment page before scheduling, and expect a full baseline visit rather than a same-day prescription.
Who Should Prescribe It
Primary care physicians manage menopausal hormone therapy and testosterone therapy routinely. Referral to gynecology, endocrinology, or urology makes sense for complex cases: prior hormone-sensitive cancer, unexplained bleeding, thrombophilia, infertility, or unclear diagnosis.
Access is the practical constraint in North Texas. Patients in Cooke County and northern Denton County often drive to Denton or the DFW metroplex for menopause-focused care, and the drive is a real reason people abandon monitoring after the first prescription. Local management through primary care in Providence Village keeps labs, exams, and dose adjustments in one place.
Symptoms rarely arrive alone. Weight gain, insulin resistance, and sleep disruption cluster with hormonal change, and a medically supervised weight loss program often changes symptom severity on its own. Cardiovascular risk factors should be assessed before starting systemic therapy, which is where a heart health evaluation fits into the workup, and complex adult comorbidities are managed through internal medicine.
What a First Appointment Involves
- A symptom inventory covering hot flashes, night sweats, sleep, mood, libido, and genitourinary symptoms
- Menstrual and surgical history, including whether you still have a uterus
- Personal and family history of clots, stroke, breast and endometrial cancer, and liver disease
- Medication and supplement review
- Blood pressure, BMI, and a focused physical exam
- Baseline labs appropriate to your sex and risk profile
- Current mammogram status for women; PSA discussion for men 40 and older
- A written plan covering route, dose, follow-up dates, and the specific symptoms that define success
Meet the clinicians who run these visits on our team page, and read our earlier explainer on hormone imbalance symptoms and when to consider therapy.
Absolute Urgent Care provides hormone therapy evaluation, on-site labs, and ongoing monitoring in Gainesville at 800 W Highway 82, 940-301-5000, and in Providence Village at 26631 US HWY 380E, Suite A, 940-686-7500.
This article is educational and does not replace evaluation by a licensed clinician. Regulatory labeling continues to change; confirm current product labeling and guidance with your prescriber before starting or stopping therapy.
Frequently Asked Questions
Did the FDA remove the warnings on hormone replacement therapy?
In November 2025 the FDA requested removal of several boxed warnings on menopausal hormone therapy products, and approved the first revised labels in February 2026. Warnings for blood clots, stroke, and gallbladder disease remain in other sections of the labeling.
What is the best age to start hormone therapy?
Current guidance favors initiation under age 60 or within 10 years of menopause, where the benefit-risk balance is most favorable for moderate-to-severe vasomotor symptoms.
Are bioidentical hormones safer than conventional HRT?
FDA-approved bioidentical products such as estradiol and micronized progesterone are regulated and dose-verified. Custom-compounded formulations, including pellets, are not FDA-approved as products, and professional societies do not recommend them when approved options exist.
Do I need a progesterone if I still have my uterus?
Yes. Systemic estrogen without a progestogen raises the risk of endometrial hyperplasia and cancer in women with an intact uterus.
How low does testosterone need to be to qualify for treatment?
The usual threshold is a fasting morning total testosterone below roughly 300 ng/dL, confirmed on a repeat morning test, together with consistent symptoms and after other causes are excluded.
How often do I need labs on hormone therapy?
Men typically require testosterone, hematocrit, and PSA checks at 3 to 6 months, then annually. Women on standard menopausal therapy do not need routine hormone level monitoring; follow-up focuses on symptoms, blood pressure, bleeding, and breast screening.
